Report Code: A12016 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Disease-modifying Agents Market
Request Now !Disease modification can be defined as treatments that affect the underlying pathophysiology of the disease and have a beneficial outcome. In the struggle to decrease the development of disease in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, multiple sclerosis, and Crohn's disease, the disease-modifying agent class, including treatments such as anti-TNF agents and immunomodulators, averting the progression of each disease and also the market is experiencing notable growth. However, the landscape has changed with the entry of disease-modifying agents. Several new disease-modifying drugs are in the line, all of which will offer important options for patients with these diseases, thus promoting the growth of the disease-modifying agents market.
COVID-19 Impact analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the disease-modifying agents market.
Top Impacting Factors
Market Trends
Promising Product Pipeline Expected to Flourish the Market
Companies are taking efforts to develop therapeutic modalities for underlying pathophysiological changes in Alzheimer’s disease and other neurodegenerative disorders.
A phase 3 study of isradipine is being carried out as a disease-modifying agent in patients with early Parkinson's disease by STEADY-PD III, funded by National Institute of Neurological Disorders and Stroke (NINDS).
In September 2020, Prothena Corporation plc declared the results of the Phase 2 PASADENA study of prasinezumab, which is the first anti-inflammatory, anti-alpha-synuclein antibody to show efficacy in patients with early Parkinson's disease.
Key Benefits of the Report
Questions answered in the disease-modifying agents Report
Disease-Modifying Agents Market Report Highlights
Aspects | Details |
---|---|
By Drug Class |
|
By Indication |
|
By Therapy Type |
|
By Route of Administration |
|
By Region |
|
By End User |
|
Key Market Players | Biogen Inc., Accord Healthcare Inc, Nordic Group Bv, Antares Pharma, Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Hospira, Inc., Fresenius Kabi, Pfizer Inc, Elan Pharma India Pvt Ltd. |
Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers